Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 9, 2026, 9:45 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 73–96 of 132 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Sarcoma, Kaposi Clear all
Completed Phase 2 Interventional

Suppression of Oral HHV8 Shedding With Valganciclovir

NCT00194467
View directory record Official record
Conditions
Human Herpesvirus 8
Interventions
valganciclovir, placebo
Drug
Lead sponsor
University of Washington
Other
Eligibility
18 Years and older · Male only
Enrollment
32 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2005
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Jan 10, 2008 · Synced Oct 9, 2026, 9:45 AM EDT
Completed Phase 1 Interventional Results available

Testing the Addition of an Experimental Medication MK-3475 (Pembrolizumab) to Usual Anti-Retroviral Medications in Patients With HIV and Cancer

NCT02595866
View directory record Official record
Conditions
AIDS-Related Non-Hodgkin Lymphoma, Clinical Stage III Cutaneous Melanoma AJCC v8, Clinical Stage IV Cutaneous Melanoma AJCC v8, Hepatocellular Carcinoma, HIV Infection, Kaposi Sarcoma, Locally Advanced Lung Non-Small Cell Carcinoma, Locally Advanced Malignant Solid Neoplasm, Metastatic Lung Non-Small Cell Carcinoma, Metastatic Malignant Solid Neoplasm, Metastatic Melanoma, Non-Hodgkin Lymphoma, Recurrent Classic Hodgkin Lymphoma, Recurrent Malignant Neoplasm, Refractory Classic Hodgkin Lymphoma, Refractory Malignant Neoplasm, Stage III Lung Cancer AJCC v8, Stage IV Lung Cancer AJCC v8, Unresectable Melanoma
Interventions
Antiretroviral Therapy, Biopsy, Biospecimen Collection, Computed Tomography, Pembrolizumab, Positron Emission Tomography
Drug · Procedure · Biological
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
58 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2024
U.S. locations
12
States / cities
Birmingham, Alabama • San Francisco, California • New Haven, Connecticut + 6 more
Source: ClinicalTrials.gov public record
Updated Aug 9, 2024 · Synced Oct 9, 2026, 9:45 AM EDT
Completed Phase 1 Interventional

Combination Chemotherapy Plus Filgrastim in Treating Patients With Advanced Solid Tumors

NCT00014456
View directory record Official record
Conditions
Bladder Cancer, Breast Cancer, Carcinoma of Unknown Primary, Esophageal Cancer, Gastric Cancer, Head and Neck Cancer, Lung Cancer, Melanoma (Skin), Ovarian Cancer, Pancreatic Cancer, Prostate Cancer, Sarcoma
Interventions
filgrastim, docetaxel, gemcitabine hydrochloride
Biological · Drug
Lead sponsor
Dartmouth-Hitchcock Medical Center
Other
Eligibility
18 Years and older
Enrollment
35 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2000 – 2005
U.S. locations
1
States / cities
Lebanon, New Hampshire
Source: ClinicalTrials.gov public record
Updated Aug 28, 2013 · Synced Oct 9, 2026, 9:45 AM EDT
Terminated Phase 1 Interventional Results available

Nivolumab and Ipilimumab in Treating Patients With HIV Associated Relapsed or Refractory Classical Hodgkin Lymphoma or Solid Tumors That Are Metastatic or Cannot Be Removed by Surgery

NCT02408861
View directory record Official record
Conditions
Advanced Malignant Solid Neoplasm, Anal Carcinoma, HIV Infection, Kaposi Sarcoma, Lung Carcinoma, Metastatic Malignant Solid Neoplasm, Recurrent Classic Hodgkin Lymphoma, Refractory Classic Hodgkin Lymphoma, Unresectable Solid Neoplasm, HIV-associated Cancers
Interventions
Biospecimen Collection, Bone Marrow Biopsy, Computed Tomography, Ipilimumab, Nivolumab, Positron Emission Tomography
Procedure · Biological
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
79 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2024
U.S. locations
32
States / cities
La Jolla, California • Los Angeles, California • Sacramento, California + 19 more
Source: ClinicalTrials.gov public record
Updated Jan 21, 2026 · Synced Oct 9, 2026, 9:45 AM EDT
Completed Phase 1Phase 2 Interventional

BMS-275291 in Treating Patients With HIV-Related Kaposi's Sarcoma

NCT00024024
View directory record Official record
Conditions
Sarcoma
Interventions
rebimastat
Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
16 Years and older
Enrollment
59 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2001
U.S. locations
3
States / cities
Chicago, Illinois • St Louis, Missouri • New York, New York
Source: ClinicalTrials.gov public record
Updated Feb 11, 2013 · Synced Oct 9, 2026, 9:45 AM EDT
Completed Phase 2 Interventional

Nicotine Skin Patch in Treating Patients With Kaposi's Sarcoma

NCT00295984
View directory record Official record
Conditions
Sarcoma
Interventions
nicotine
Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years to 78 Years
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Jun 20, 2013 · Synced Oct 9, 2026, 9:45 AM EDT
Completed Phase 3 Interventional

Paclitaxel Compared With Doxorubicin in Treating Patients With Advanced AIDS-Related Kaposi's Sarcoma

NCT00003350
View directory record Official record
Conditions
AIDS-related Kaposi Sarcoma
Interventions
paclitaxel, pegylated liposomal doxorubicin hydrochloride, laboratory biomarker analysis, quality-of-life assessment
Drug · Other · Procedure
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
240 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 1999
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jan 10, 2013 · Synced Oct 9, 2026, 9:45 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Spectroscopy With Surface Coils and Decoupling

NCT00581815
View directory record Official record
Conditions
Adrenal Cortical Cancer, Brain Cancer, Breast Cancer, CNS Cancer, Colon Cancer, HEENT Cancer, Hodgkin's Disease, Kaposi's Sarcoma, Liver Cancer, Lung Cancer, Non-Hodgkin's Lymphoma, Ovarian Cancer, Pancreatic Cancer, Prostate Cancer, Rectal Cancer, Renal Cancer, Sarcoma, Squamous Cell Carcinoma, Thyroid Cancer
Interventions
Proton-decoupled 31P MRS at 1.5T, 1H Spectroscopy at 1.5T and 3T
Device
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years and older
Enrollment
582 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
1997 – 2014
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Dec 28, 2015 · Synced Oct 9, 2026, 9:45 AM EDT
Completed Phase 3 Interventional

A Study of AZT in HIV-Infected Patients With AIDS-Related Kaposi's Sarcoma

NCT00000994
View directory record Official record
Conditions
HIV Infections
Interventions
Zidovudine
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years and older · Male only
Enrollment
240 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Ends 1990
U.S. locations
22
States / cities
Los Angeles, California • San Diego, California • San Francisco, California + 12 more
Source: ClinicalTrials.gov public record
Updated Nov 4, 2021 · Synced Oct 9, 2026, 9:45 AM EDT
Completed Phase 1 Interventional

A Study of AZT Plus Human Interferon Alpha in the Treatment of AIDS-Related Kaposi's Sarcoma

NCT00001113
View directory record Official record
Conditions
Sarcoma, Kaposi, HIV Infections
Interventions
Interferon alfa-2a, Zidovudine, Interferon alfa-n1
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years and older
Enrollment
48 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Ends 1990
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Nov 4, 2021 · Synced Oct 9, 2026, 9:45 AM EDT
Completed Phase 3 Interventional

A Randomized Phase III Clinical Trial of Daunoxome Versus Combination Chemotherapy With Adriamycin/Bleomycin/Vincristine (ABV) in the Treatment of HIV-Associated Kaposi's Sarcoma.

NCT00002093
View directory record Official record
Conditions
Sarcoma, Kaposi, HIV Infections
Interventions
Daunorubicin (liposomal), Bleomycin sulfate, Vincristine sulfate, Doxorubicin hydrochloride
Drug
Lead sponsor
Nexstar Pharmaceuticals
Industry
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
U.S. locations
13
States / cities
Tucson, Arizona • Los Angeles, California • Palm Springs, California + 9 more
Source: ClinicalTrials.gov public record
Updated Jun 24, 2005 · Synced Oct 9, 2026, 9:45 AM EDT
Completed Phase 2 Interventional Results available

Effects of Maraviroc (MVC) on HIV-related Kaposi's Sarcoma (KS)

NCT01276236
View directory record Official record
Conditions
Kaposi's Sarcoma
Interventions
Maraviroc
Drug
Lead sponsor
University of California, San Francisco
Other
Eligibility
18 Years and older
Enrollment
13 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2015
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Mar 5, 2021 · Synced Oct 9, 2026, 9:45 AM EDT
Completed Phase 2 Interventional

Phase II Study of Zidovudine and Recombinant Alpha-2A Interferon in the Treatment of Patients With AIDS-Associated Kaposi's Sarcoma

NCT00000687
View directory record Official record
Conditions
Sarcoma, Kaposi, HIV Infections
Interventions
Interferon alfa-2a, Zidovudine
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
12 Years and older
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Ends 1993
U.S. locations
9
States / cities
Miami, Florida • Baltimore, Maryland • Boston, Massachusetts + 6 more
Source: ClinicalTrials.gov public record
Updated Nov 3, 2021 · Synced Oct 9, 2026, 9:45 AM EDT
Recruiting Phase 1 Interventional

Pomalidomide and Nivolumab in People With Virus-Associated Malignancies With or Without HIV

NCT04902443
View directory record Official record
Conditions
Viral Associated Malignancies, Kaposi Sarcoma, EBV/KSHV-associated Lymphomas
Interventions
Pomalidomide, Nivolumab
Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years to 99 Years
Enrollment
58 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2027
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Sep 17, 2026 · Synced Oct 9, 2026, 9:45 AM EDT
Completed Phase 1Phase 2 Interventional Results available

Lenalidomide in Treating Patients With AIDS-Associated Kaposi's Sarcoma

NCT01057121
View directory record Official record
Conditions
AIDS-Related Kaposi Sarcoma, Recurrent Kaposi Sarcoma
Interventions
Lenalidomide
Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
38 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2014
U.S. locations
13
States / cities
Los Angeles, California • San Diego, California • San Francisco, California + 9 more
Source: ClinicalTrials.gov public record
Updated Feb 8, 2022 · Synced Oct 9, 2026, 9:45 AM EDT
Not yet recruiting Phase 2 Interventional

Nirogacestat in Patients With Kaposi Sarcoma

NCT07539454
View directory record Official record
Conditions
AIDS-Related Kaposi Sarcoma, Skin Kaposi Sarcoma
Interventions
Biospecimen Collection, Chest Radiography, Computed Tomography, Nirogacestat, Skin Biopsy
Procedure · Drug
Lead sponsor
AIDS Malignancy Consortium
Network
Eligibility
18 Years and older
Enrollment
28 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2030
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated May 28, 2026 · Synced Oct 9, 2026, 9:45 AM EDT
Completed Phase 3 Interventional

A Study of DOX-SL in the Treatment of AIDS-Related Kaposi's Sarcoma

NCT00002319
View directory record Official record
Conditions
Sarcoma, Kaposi, HIV Infections
Interventions
Doxorubicin hydrochloride (liposomal)
Drug
Lead sponsor
Sequus Pharmaceuticals
Industry
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
U.S. locations
33
States / cities
Berkeley, California • Beverly Hills, California • Encino, California + 17 more
Source: ClinicalTrials.gov public record
Updated Jun 24, 2005 · Synced Oct 9, 2026, 9:45 AM EDT
Completed Phase 1 Interventional

A Phase I Study of TNP-470 in the Treatment of AIDS-Associated Kaposi's Sarcoma

NCT00000763
View directory record Official record
Conditions
Sarcoma, Kaposi, HIV Infections
Interventions
TNP-470
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
12 Years and older
Enrollment
42 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Ends 1997
U.S. locations
6
States / cities
Los Angeles, California • Chicago, Illinois • Boston, Massachusetts + 2 more
Source: ClinicalTrials.gov public record
Updated Nov 3, 2021 · Synced Oct 9, 2026, 9:45 AM EDT
Completed Phase 2 Interventional

High-dose ICE With Amifostine

NCT00003657
View directory record Official record
Conditions
Bladder Cancer, Brain and Central Nervous System Tumors, Carcinoma of Unknown Primary, Extragonadal Germ Cell Tumor, Head and Neck Cancer, Kidney Cancer, Lung Cancer, Ovarian Cancer, Sarcoma, Testicular Germ Cell Tumor, Unspecified Adult Solid Tumor, Protocol Specific
Interventions
filgrastim, Amifostine, Carboplatin, Etoposide, Ifosfamide, peripheral blood stem cell transplantation
Biological · Drug · Procedure
Lead sponsor
Dana-Farber Cancer Institute
Other
Eligibility
18 Years to 55 Years
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1998 – 2002
U.S. locations
3
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jan 20, 2017 · Synced Oct 9, 2026, 9:45 AM EDT
Completed Phase 1 Interventional

Sirolimus in Treating Patients With HIV-Related Kaposi's Sarcoma

NCT00450320
View directory record Official record
Conditions
Sarcoma
Interventions
sirolimus
Drug
Lead sponsor
AIDS Malignancy Consortium
Network
Eligibility
18 Years and older
Enrollment
7 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2009
U.S. locations
3
States / cities
La Jolla, California • Boston, Massachusetts • New York, New York
Source: ClinicalTrials.gov public record
Updated Aug 29, 2014 · Synced Oct 9, 2026, 9:45 AM EDT
Recruiting Phase 1Phase 2 Interventional

PDS01ADC Monotherapy and in Combination With M7824 in Advanced Kaposi Sarcoma

NCT04303117
View directory record Official record
Conditions
Kaposi Sarcoma
Interventions
PDS01ADC, M7824
Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years to 99 Years
Enrollment
80 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2028
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Aug 24, 2026 · Synced Oct 9, 2026, 9:45 AM EDT
Completed Phase 1 Interventional

Study to Evaluate Safety and Tolerability of XmAb13676 (Plamotamab) in Patients With CD20-expressing Hematologic Malignancies

NCT02924402
View directory record Official record
Conditions
B-cell Non-Hodgkins Lymphoma, Chronic Lymphocytic Leukemia
Interventions
XmAb13676
Biological
Lead sponsor
Xencor, Inc.
Industry
Eligibility
18 Years and older
Enrollment
154 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2024
U.S. locations
10
States / cities
La Jolla, California • Jacksonville, Florida • Atlanta, Georgia + 7 more
Source: ClinicalTrials.gov public record
Updated Nov 13, 2024 · Synced Oct 9, 2026, 9:45 AM EDT
Terminated Not applicable Interventional

Infrared Thermography in Finding Skin Lesions in Patients With Kaposi's Sarcoma

NCT00265902
View directory record Official record
Conditions
Sarcoma
Interventions
diagnostic imaging
Procedure
Lead sponsor
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Other
Eligibility
18 Years to 120 Years
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2006
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 20, 2019 · Synced Oct 9, 2026, 9:45 AM EDT
Completed Phase 2 Interventional

A Study of Doxorubicin in the Treatment of AIDS-Related Kaposi's Sarcoma

NCT00000996
View directory record Official record
Conditions
Sarcoma, Kaposi, HIV Infections
Interventions
Doxorubicin hydrochloride
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years and older
Enrollment
48 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Ends 1990
U.S. locations
12
States / cities
Los Angeles, California • San Francisco, California • Washington D.C., District of Columbia + 7 more
Source: ClinicalTrials.gov public record
Updated Nov 4, 2021 · Synced Oct 9, 2026, 9:45 AM EDT